Compare FPI & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FPI | BBNX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.2M | 493.1M |
| IPO Year | 2013 | N/A |
| Metric | FPI | BBNX |
|---|---|---|
| Price | $11.03 | $11.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | N/A | ★ $26.22 |
| AVG Volume (30 Days) | 510.9K | ★ 965.2K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $52,178,000.00 | N/A |
| Revenue This Year | N/A | $34.99 |
| Revenue Next Year | N/A | $34.47 |
| P/E Ratio | $18.13 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.37 | $8.89 |
| 52 Week High | $13.23 | $32.71 |
| Indicator | FPI | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 36.89 | 40.15 |
| Support Level | $10.49 | $9.91 |
| Resistance Level | $11.15 | $15.53 |
| Average True Range (ATR) | 0.36 | 0.62 |
| MACD | -0.19 | 0.30 |
| Stochastic Oscillator | 13.69 | 67.66 |
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.